by Rawamino | Nov 1, 2025 | Peptides
Introduction Aberrant redox signaling has long been implicated in experimental models of neurodegeneration, where excessive reactive oxygen and nitrogen species disturb proteostasis, mitochondrial function, and kinase networks. Within this context, the non-receptor...
by Rawamino | Oct 31, 2025 | Peptides
Introduction Neurodegenerative disorders such as Alzheimer’s disease (AD) are characterized by progressive neuronal loss and sustained neuroinflammation, a process in which glial activation contributes to synaptic dysfunction and neuronal decline. In experimental...
by Rawamino | Oct 31, 2025 | Peptides
Introduction Dopaminergic neuron loss within the nigrostriatal system is a defining feature of Parkinsonian neurodegeneration in laboratory models. Converging evidence indicates that programmed cell death (apoptosis) and chronic glial activation cooperate to erode...
by Rawamino | Oct 31, 2025 | Peptides
Introduction The interleukin-23 (IL-23) signaling axis is central to immune modulation, influencing chronic inflammatory responses and maintaining Th17-cell activity. Overactivation of this pathway is implicated in inflammatory skin conditions, where persistent...
by Rawamino | Oct 30, 2025 | Peptides
Introduction Aging remains one of the most significant biological risk factors associated with neurodegenerative conditions. Across the lifespan, progressive molecular alterations—ranging from mitochondrial decline to chronic low-grade inflammation—create a cellular...
by Rawamino | Oct 30, 2025 | Peptides
Introduction Synucleinopathies such as Parkinson’s disease (PD), dementia with Lewy bodies, and multiple system atrophy are characterized by abnormal aggregation of α-synuclein (αSyn) within neuronal and glial compartments. Mounting evidence suggests that soluble...
